Opendata, web and dolomites

VACCELERAID

A novel vaccine technology leading to accelerated availability of vaccines and improved delivery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VACCELERAID project word cloud

Explore the words cloud of the VACCELERAID project. It provides you a very rough idea of what is the project "VACCELERAID" about.

earlier    updated    licensing    faster    demands    capsid    global    pharma    periods    obtain    specified    sudden    initiation    market    budget    milestone    accelerated    sv40    agreements    vaccination    time    delays    seasonal    campaigns    approval    evaluations    pandemics    solutions    prepare    house    ing    world    diseases    hereto    purpose    vaccine    rna    met    input    area    proteins    self    markets    plan    attractiveness    regulatory    business    infectious    novartis    assembly    co    consuming    definitely    marketing    vaccines    unknown    fast    intended    encounter    outbreaks    health    acid    made    additional    view    advantage    highlight    offers    dangerous    pasteur    validating    times    competitors    platform    people    nucleic    sanofi    active    model    payments    public    manufacturing    full    gza    technologies    professionals    introduction    shortened    influenza    common    ip    frequently    feasibility    gsk    wishes    companies    risk    lives    royalties    pose    strategy    receive    validated    start   

Project "VACCELERAID" data sheet

The following table provides information about the project.

Coordinator
GEZA AD LTD 

Organization address
address: SIRKIN 19
city: GIVATAIYM
postcode: 53251
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-11-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GEZA AD LTD IL (GIVATAIYM) coordinator 50˙000.00

Map

 Project objective

Common to current manufacturing technologies for vaccines is the long lead-time before they were made available or novel vaccines could be made available to the public. Current methods are very time consuming and frequently encounter problems with scale-up, in particular if sudden demands have to be met. However, the ability to start vaccination campaigns fast – and earlier than currently possible – is particularly important in view of seasonal influenza, influenza pandemics or sudden outbreaks of dangerous, hereto unknown infectious diseases. Resulting delays definitely pose a high risk for health and lives of many people. To provide solutions to these world-wide challenges is of European and global interest and GZA offers such a response: The technology is based on self-assembly of SV40 capsid proteins around a given nucleic acid and has several additional applications; however, it will be validated here in the area of vaccination with RNA. The main advantage of GZA’s novel vaccine technology platform is that it enables strongly shortened manufacturing periods and accelerated market introduction of a novel vaccine (e.g., 2-3 times faster manufacturing for novel influenza vaccines). The business model is based on developing and validating the technology for a given purpose in-house and receive milestone payments and royalties specified in co-development and licensing agreements with established pharma companies active in the vaccine sector (such as GSK, Novartis or Sanofi Pasteur). Most importantly, in the feasibility assessment applied for here GZA wishes to further detail the business plan with updated evaluations of markets, competitors, IP, a project/development plan and budget to further highlight the attractiveness of the business case and to prepare initiation of a full development program in phase 2. Furthermore, it is intended to obtain input from experienced regulatory professionals and draft a potential regulatory strategy aiming at marketing approval.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VACCELERAID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VACCELERAID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More